Literature DB >> 33446816

Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.

Yi Liu1, Peipei Zhang2, Yinghao Zhang1, Lichuan Zheng1, Wenbo Xu1, Dongtao Hou3, Zhengjun Kang4.   

Abstract

Prostate cancer (PCa) is the most prevalent cancer among males and the survival period of PCa has been significantly extended. However, the probability of suffering from second primary malignancies (SPMs) has also increased. Therefore, we downloaded SPM samples from the SEER database and then retrospectively analyzed the general characteristics of 34,891 PCa patients diagnosed between 2000 and 2016. After excluding cases with unknown clinical information, 2203 patients were used to construct and validate the overall survival (OS) nomogram of SPM patients after PCa. We found that approximately 3.69% of PCa patients were subsequently diagnosed with SPMs. In addition, the three most prevalent sites of SPM were respiratory and intrathoracic organs, skin, and hematopoietic system. The top three histological types of SPMs were squamous cell carcinoma, adenoma and adenocarcinoma, nevi and melanoma. Through univariate and multivariate Cox regression analysis, we found that the site of SPM, age, TNM stage, SPM surgery history, and PCa stage were associated with the OS of SPM. By virtue of these factors, we constructed a nomogram to predict the OS of SPM. The C-index in the training set and validation set were 0.824 (95CI, 0.806-0.842) and 0.862 (95CI, 0.840-0.884), respectively. Furthermore, we plotted the receiver operating characteristic curve (ROC) and the area under curve (AUC) which showed that our model performed well in assessing the 3-year (0.861 and 0.887) and 5-year (0.837 and 0.842) OS of SPMs in the training and validation set. In summary, we investigated the general characteristics of SPMs and constructed a nomogram to predict the prognosis of SPM following PCa.

Entities:  

Year:  2021        PMID: 33446816      PMCID: PMC7809269          DOI: 10.1038/s41598-020-80534-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  46 in total

1.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

Review 2.  Treatment of Advanced Prostate Cancer.

Authors:  Min Yuen Teo; Dana E Rathkopf; Philip Kantoff
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

Review 3.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

4.  Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer.

Authors:  Wayne S Kendal; Libni Eapen; Robert Macrae; Shawn Malone; Garth Nicholas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-20       Impact factor: 7.038

5.  RB1 mutations and second primary malignancies after hereditary retinoblastoma.

Authors:  Charlotte J Dommering; Tamara Marees; Annemarie H van der Hout; Saskia M Imhof; Hanne Meijers-Heijboer; Peter J Ringens; Flora E van Leeuwen; Annette C Moll
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

6.  Incidence of second malignancies for prostate cancer.

Authors:  Mieke Van Hemelrijck; Anita Feller; Hans Garmo; Fabio Valeri; Dimitri Korol; Silvia Dehler; Sabine Rohrmann
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

7.  Risk of Second Primary Cancer among Prostate Cancer Patients in Korea: A Population-Based Cohort Study.

Authors:  Jae Young Joung; Jiwon Lim; Chang-Mo Oh; Kyu-Won Jung; Hyunsoon Cho; Sung Han Kim; Ho Kyung Seo; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Young-Joo Won
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

8.  Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis.

Authors:  Nina-Sophie Hegemann; Anne Schlesinger-Raab; Ute Ganswindt; Claudia Hörl; Stephanie E Combs; Dieter Hölzel; Jürgen E Gschwend; Christian Stief; Claus Belka; Jutta Engel
Journal:  Radiat Oncol       Date:  2017-01-03       Impact factor: 3.481

9.  Excessive risk of second primary cancers in young-onset colorectal cancer survivors.

Authors:  Xingkang He; Wenrui Wu; Yu'e Ding; Yue Li; Jianmin Si; Leimin Sun
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

Review 10.  Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.

Authors:  Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam
Journal:  BMJ       Date:  2016-03-02
View more
  4 in total

1.  Second primary malignancy among malignant solid tumor survivors aged 85 years and older.

Authors:  Zhijia Zhang; Fei Liu; Yanlin Qu; Liqian Qiu; Liqun Zhang; Qiao Yang
Journal:  Sci Rep       Date:  2021-10-05       Impact factor: 4.379

2.  Clinicopathological Features, Prognostic Factors and Survival in Patients With Pancreatic Cancer Bone Metastasis.

Authors:  Ying Ren; Shicheng Wang; Bo Wu; Zhan Wang
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

Review 3.  An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations.

Authors:  Fabiana Baroni Alves Makdissi; Silvana S Santos; Almir Bitencourt; Fernando Augusto Batista Campos
Journal:  Int Braz J Urol       Date:  2022 Sep-Oct       Impact factor: 3.050

4.  Nomogram for predicting the overall survival of patients with early-onset prostate cancer: A population-based retrospective study.

Authors:  Yongtao Hu; Qiao Qi; Yongshun Zheng; Haoran Wang; Jun Zhou; Zongyao Hao; Jialin Meng; Chaozhao Liang
Journal:  Cancer Med       Date:  2022-03-23       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.